Antifungal firm F2G attracts Novartis despite Neutec flop

The Manchester, UK-based antifungal drug discovery firm F2G has secured a $30 million financing round to advance its early-stage pipeline into the clinic. The company hopes to begin Phase I trials next year of a drug candidate to treat Aspergillus infections from its F3 series, a group of small-molecule compounds based on novel chemistry and a novel target.